Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 42, Issue -, Pages 461-467Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BST20140027
Keywords
epilepsy; glyoxalase I; glyoxalase inhibitor; methylglyoxal; neuropsychiatric disorder
Categories
Funding
- National Institutes of Health [RO1NS058505, RO1MH079103, RO1NS076517, RO1MH096463]
Ask authors/readers for more resources
Many current pharmacological treatments for neuropsychiatric disorders, such as anxiety and depression, are limited by a delayed onset of therapeutic effect, adverse side effects, abuse potential or lack of efficacy in many patients. These off-target effects highlight the need to identify novel mechanisms and targets for treatment. Recently, modulation of Glo-1 (glyoxalase I) activity was shown to regulate anxiety-like behaviour and seizure-susceptibility in mice. These effects are likely to be mediated through the regulation of MG (methylglyoxal) by Glo1, as MG acts as a competitive partial agonist at GABA(A) (gamma-aminobutyric acid A) receptors. Thus modulation of MG by Glo1 represents a novel target for treatment. In the present article, we evaluate the therapeutic potential of indirectly modulating MG concentrations through Glol inhibitors for the treatment of neuropsychiatric disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available